[ad_1]
DermTech, Inc. (NASDAQ:DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the grant to one new employee of restricted stock units representing the contingent right to receive up to an aggregate of 51,934 shares of its common stock under its 2022 Inducement Equity Incentive Plan, or the 2022 Inducement Plan. The restricted stock units were approved by DermTech’s Compensation Committee on March 23, 2022 and granted as inducements material to the employee’s acceptance of employment with DermTech in accordance with Nasdaq Listing Rule 5635 (c)(4).
The 51,934 restricted stock units shall vest as follows: (i) …
Full story available on Benzinga.com
[ad_2]
Source link
